Cuprina Holdings (Cayman) Limited Class A (CUPR) AI Stock Analysis

• Market Cap: $3.67M
• Dividend Yield: N/A
• Average Volume (3M): 2.90M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 7,365,000
• 10 Day Avg. Volume: 197,362
• 30 Day Avg. Volume: 2,899,437
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.61 ▲(21.00% Upside)

Cuprina Holdings is currently facing severe financial difficulties, with declining revenues, negative profitability, and high leverage risk. The technical analysis indicates a bearish trend, with the stock trading below key moving averages and nearing oversold conditions. The negative P/E ratio and lack of dividend yield further highlight valuation concerns. These factors collectively contribute to a low overall stock score.

Positive Factors

Product and Technology Diversification

Diversifying the product and technology portfolio can enhance market resilience and open new revenue streams, supporting long-term growth.

Joint Venture with Aiodine

The joint venture positions Cuprina in the expanding wound care market, leveraging Aiodine's technology to potentially capture significant market share.

Medical Waste Recycling Rights

Exclusive rights to innovative recycling technology can drive growth by tapping into the rising demand for sustainable waste management solutions.

Negative Factors

Declining Revenue

Significant revenue decline indicates challenges in maintaining market position and could impact long-term financial sustainability.

High Leverage Risk

High leverage risk limits financial flexibility and increases vulnerability to economic downturns, threatening long-term viability.

Nasdaq Noncompliance

Noncompliance with Nasdaq listing requirements could lead to delisting, reducing investor confidence and access to capital markets.

Cuprina Holdings (Cayman) Limited Class A Business Overview & Revenue Model

Company Description

Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company dedicated to developing and commercializing innovative products for managing chronic wounds. The company manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, used as a biological debridement tool for chronic wounds. Additionally, Cuprina operates in the health and beauty sectors, offering cosmeceutical products.

How the Company Makes Money

Cuprina Holdings (Cayman) Limited Class A Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Cuprina Holdings (Cayman) Limited Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BDRX	45 Neutral	$3.38M	-0.06	-60.37%	―	-100.00%	86.75%
CUPR	41 Neutral	$3.67M	-4.81	―	―	―	―
HSDT	39 Underperform	$118.54M	>-0.01	―	―	87.45%	72.30%
SHPH	32 Underperform	$2.69M	-0.08	-9999.00%	―	―	79.31%
SLRX	30 Underperform	$3.83M	-0.02	-139.55%	―	―	68.08%
WINT	28 Underperform	$1.31M	>-0.01	―	―	―	99.09%

Cuprina Holdings (Cayman) Limited Class A Corporate Events

Cuprina Holdings Releases Mid-2025 Financial Results

Cuprina Holdings (Cayman) Limited released its unaudited financial results for the six months ending June 30, 2025, on December 9, 2025. The report includes financial statements and management’s analysis, highlighting the company’s financial condition and operational results for the period. The announcement provides stakeholders with insights into Cuprina’s financial performance and strategic positioning during the first half of 2025.

Cuprina Holdings Receives Nasdaq Notice for Bid Price Deficiency

On November 26, 2025, Cuprina Holdings received a notice from Nasdaq indicating that its Class A ordinary shares had fallen below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has been given a 180-day compliance period, until May 26, 2026, to rectify this issue. If compliance is not regained, Cuprina may qualify for an additional 180-day grace period by meeting other listing standards and potentially executing a reverse stock split. The notification does not immediately affect the trading of Cuprina’s shares, which will continue under the symbol ‘CUPR.’ Cuprina is actively exploring options to regain compliance, though there is no assurance of success.

Cuprina Holdings Forms Joint Venture with Aiodine for Iodine-Based Wound Care

On November 18, 2025, Cuprina Holdings announced a joint venture with Aiodine Laboratory to develop and market a novel iodine-based solution for wound care therapy. This partnership aims to utilize Aiodine’s proprietary iodine technology to create antiseptic solutions for chronic and acute wounds, with plans to begin clinical studies for regulatory approval in 2026. Cuprina will handle global sales and marketing, while Aiodine provides technical expertise. The iodine solution has shown promising results in a study, indicating significant wound healing and reduced infection, potentially positioning Cuprina to expand its offerings in the growing wound care market, valued at $21 billion in 2024 and projected to reach $36 billion by 2032.

Cuprina Holdings Changes Auditors Amid Smooth Transition

Cuprina Holdings (Cayman) Limited announced the dismissal of their independent registered public accounting firm, Kreit & Chiu CPA LLP, effective October 15, 2025. The decision was approved by the company’s board of directors, and there were no disagreements or reportable events with the firm in the past two fiscal years. Concurrently, the company appointed J&S Associate PLT as the new independent registered public accounting firm to audit the financial statements for the fiscal year ending December 31, 2025. This transition is expected to proceed smoothly, as there were no prior consultations with J&S regarding any reportable matters.

Cuprina Holdings Secures Exclusive Medical Waste Recycling Rights in Southeast Asia

On September 9, 2025, Cuprina Holdings announced it has secured exclusive rights to Southeast Asia’s first UNIDO/GEF-demonstrated medical waste recycling technology. This technology, licensed from Zhejiang Heliang Technology Co., Ltd., offers an environmentally friendly alternative to incineration by using high-temperature steam treatment to recycle medical waste into high-value resins. Cuprina plans to establish Singapore as a hub for this technology, aiming to capitalize on the region’s tightening environmental standards and the growing medical waste management market.